در هيپرلپيدمي B و آپو A-I و تجويز توام آنها روي ليپوپروتيين ها، آپو C مقايسه اثرات اسيدهاي چرب امگا - 3، ويتامين

Effects of omega-3 fatty acids and vitamin C administration on lipoproteins, apo A-I and apo B in hyperlipidemia

Introducation: The control of hyperlipidemia is vital in CVD patients. Omega-3 fatty acids (O3FAs) have desirable effects on serum triglycerides (TG), thrombosis and arrhytharrythmia but lead to an increase in serum LDL and apo B as well. Vitamin C can induce LDL receptor activity of the liver and catabolize LDL particles. To determine the effects of adminstration of O3FAs, Vitamin C, and O3FAs+ vitamin C on serum levels of LDL, apo B, other serum lipids and compare these effects, the present study was performed at the Tehran University of Medical Sciences from 2000 to 2001. Material and Methods: In a double-blind, placebo controlled trial with parallel design, 68 hyperlipidemic patients [total cholestrol (TC) and triglycerides (TG) greater than 200 mg/dL] were randomly assigned to receive daily 500 mg vitamin C, 1g O3FAs, 500 mg vitamin C + 1 g O3FAs or placebo (control) for 10 weeks. Fasting blood samples were collected at the beginning and at the end of this period. TG, TC, LDL, HDL were enzymatically, vitamin C calorimetrically, apo B and apo A-I immunoturbidometrically measured. For statistical analysis, ANOVA, paired t test, Chi square and repeated measurement ANOVA were used. Results: There were no significant changes during the study in pattern of food consumption, socioeconomic and anthropometric indices. There was a significant increase in the blood vitamin C level at the end of the study, in comparison to the initial value in vitamin C (p=0.001) and vitamin C + O3FAs (p=0.02) groups. There was a significant difference in the serum TC (p=0.004), apo B (p=0.005) and decrease in apo A-Ilapo B (p=0.05) at the end of the study in comparion to the initial values as well as a significant increase in blood vitamin C compared to the control group (p=0.01). At the end of the study in O3FAs group, the TGIHDL and apo B respectively had significant decreases as compared to the beginning (p=0.04, p=0.05, respectively) and TGIHDL of this group at the end of the study significant decereased compared to the control group (p=0.04). There was no significant difference in HDL, LDL, apo A-I and LDL/HDL during the study in each group. Conclusion: Simultaneous administration of O3FAs and vitamin C had no beneficial effect on the lipid profile of hyperlipidemic patients, but 1 g purified O3FAs daily for 10 weeks is a beneficial supplement for decreasing TG and TGIHDL without any increase in LDL and apo B. 500 mg vitamin C for more than 10 weeks possibly decreases TC and apo B significantly in hyperlipidemic patients as compared to the control group.